Governed therapeutic programme control plane
—typed capabilities
—deployed surfaces
—provider integrations
0fabricated validation claims
Turn target evidence into an executable, reviewable development programme.
Compare modalities, connect molecular design with experiments and translation, and preserve every assumption, model run, artifact and decision in one living programme twin.
One asset identity
Target, indication, TPP, modality alternatives and every revision remain connected.
Prediction-to-outcome closure
Freeze predictions before experiments, ingest reviewed observations and record residuals.
Accountable decisions
Consequential dispositions require evidence, uncertainty and independent human review.
FLAGSHIP EXECUTION
Two golden paths. One evidence spine.
Begin with complete small-molecule and antibody programmes. Extend the same durable identity, artifact and decision architecture to additional modalities.
SMALL MOLECULE GOLDEN PATH
Small Molecule Therapeutic Programme
Loading the controlled path…
LIVING PROGRAMME TWIN
Every scientific object has lineage and consequence.
The operating system is not a flat list of models. It is a connected, revisioned record of what the programme believed, executed, observed and decided.
Claims & hypotheses
Causal evidence, contradictions, assumptions and falsification criteria.
Modality alternatives
MCDA, confidence, sensitivity, counterfactuals and rank reversals.
Runs & artifacts
Exact providers, versions, inputs, hashes, state, QC and outputs.
Experiments & outcomes
Frozen predictions, approved protocols, observations and residuals.
Decision objects
Alternatives, consequence of error, independent review and disposition.
MULTI-AXIS READINESS
Deployed does not automatically mean scientifically qualified.
Every capability is evaluated across separate technical, scientific, operational, security, licensing and change-control dimensions.
—deployed
—configurable
—unavailable / roadmap
A green endpoint is not a regulatory claim. Context of use, prospective evidence and qualified review remain mandatory.
PUBLIC EVIDENCE LEDGER
Compete through measured outcomes—not tool counts.
Frozen datasets, exact versions, predefined metrics, failures, exclusions and prospective results belong in the same evidence record.
Checking the public benchmark ledger…
SCIENTIFIC TRUST
Ambitious software with explicit boundaries.
External providers, GPU runners, laboratories and roadmap capabilities are never represented as configured without accepted technical, security and scientific evidence.
Prototype quarantine
Random or unqualified legacy modules cannot enter executable therapeutic workflows.
Exact identity
Model, provider, version, parameters, inputs, container, logs and artifacts remain linked.
Prospective closure
Predictions are compared with approved real observations—not retrospective storytelling.
Human authority
No autonomous candidate nomination, experiment approval, clinical dose or trial authorization.
THERAPEUTIC DESIGN OS
Build a programme that can explain what changed—and why.
Move from target evidence to a controlled therapeutic plan with persistent lineage, measurable outcomes and accountable decisions.
Open the programme workspace